COMPLETED

The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

Conditions

Sudden Cardiac Death Cardiac Arrhythmia Electrophysiology Study Genetics

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Sudden cardiac death (SCD) remains a major cause of mortality within developed nations despite aggressive efforts to reduce its societal burden. Despite extensive clinical and genetic investigations, a subgroup of cardiac arrests remain unexplained, highlighting the potential contribution of additional cardiac conditions that may not be identified with contemporary diagnostic algorithms. The EPS ARREST study aims to evaluate the role of invasive electrophysiology study within this patient population.

Official Title

The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

Quick Facts

Study Start:2017-05-01

Study Completion:2025-06-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT03079414

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Unexplained cardiac arrest requiring cardioversion or defibrillation 2. Willing and able to sign informed consent	1. Coronary artery disease (stenosis \> 50%) and clinical findings consistent with an ischemic arrest 2. Reduced left ventricular function (left ventricular ejection fraction \< 50%) on echocardiogram or cardiac MRI. 3. Persistent resting QTc \> 460 msec for males and 480 msec for females 4. Resting QTc \< 350 msec 5. Type I Brugada ECG with \>/= 2 mm ST elevation in V1 and/or V2 (Spontaneous or Drug-Induced) 6. Polymorphic or bidirectional ventricular tachycardia observed with exertion on exercise treadmill testing 7. Clinical, electrocardiographic, and/or imaging findings consistent with a diagnosis of arrhythmogenic right ventricular cardiomyopathy 8. Myocarditis 9. Reversible cause of cardiac arrest such as marked hypokalemia (\<2.8 mmol/l) or drug overdose sufficient in severity without other cause to explain the cardiac arrest. 10. Arrhythmic mitral valve prolapse syndrome 11. Documented ventricular fibrillation initiated by a short-coupled premature ventricular contraction

Inclusion Criteria

Exclusion Criteria

1. Unexplained cardiac arrest requiring cardioversion or defibrillation
2. Willing and able to sign informed consent

1. Coronary artery disease (stenosis \> 50%) and clinical findings consistent with an ischemic arrest
2. Reduced left ventricular function (left ventricular ejection fraction \< 50%) on echocardiogram or cardiac MRI.
3. Persistent resting QTc \> 460 msec for males and 480 msec for females
4. Resting QTc \< 350 msec
5. Type I Brugada ECG with \>/= 2 mm ST elevation in V1 and/or V2 (Spontaneous or Drug-Induced)
6. Polymorphic or bidirectional ventricular tachycardia observed with exertion on exercise treadmill testing
7. Clinical, electrocardiographic, and/or imaging findings consistent with a diagnosis of arrhythmogenic right ventricular cardiomyopathy
8. Myocarditis
9. Reversible cause of cardiac arrest such as marked hypokalemia (\<2.8 mmol/l) or drug overdose sufficient in severity without other cause to explain the cardiac arrest.
10. Arrhythmic mitral valve prolapse syndrome
11. Documented ventricular fibrillation initiated by a short-coupled premature ventricular contraction

Contacts and Locations

Principal Investigator

Jason D Roberts, MD MAS

PRINCIPAL_INVESTIGATOR

Western University

Andrew D Krahn, MD

STUDY_DIRECTOR

University of British Columbia

Melvin M Scheinman, MD

STUDY_DIRECTOR

University of California, San Francisco

Study Locations (Sites)

UCLA Medical Center

Los Angeles, California, 90095

United States

UC San Diego Health System

San Diego, California, 92037

United States

UCSF Medical Center

San Francisco, California, 94143-0124

United States

Stanford University

Stanford, California, 94305

United States

Queen's Medical Center

Honolulu, Hawaii, 96813

United States

Massachusetts General Hospital

Boston, Massachusetts, 02114

United States

Regions Hospital

St. Paul, Minnesota, 55101

United States

Oregon Health & Science University

Portland, Oregon, 97239

United States

Vanderbilt University Medical Center

Nashville, Tennessee, 37232

United States

University of Utah

Salt Lake City, Utah, 84132

United States

Inova Heart and Vascular Institute

Falls Church, Virginia, 22042

United States

Collaborators and Investigators

Sponsor: Western University, Canada

Jason D Roberts, MD MAS, PRINCIPAL_INVESTIGATOR, Western University
Andrew D Krahn, MD, STUDY_DIRECTOR, University of British Columbia
Melvin M Scheinman, MD, STUDY_DIRECTOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-05-01

Study Completion Date2025-06-01

Study Record Updates

Study Start Date2017-05-01

Study Completion Date2025-06-01

Terms related to this study

Keywords Provided by Researchers

Sudden Cardiac Death
Cardiac Arrhythmia
Electrophysiology Study
Genetics

Additional Relevant MeSH Terms

Sudden Cardiac Death